MOONLAKE IMMUNOTHERAPEUTICS Stock-Based Compensation
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Stock-Based Compensation of $15.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-10
- MOONLAKE IMMUNOTHERAPEUTICS share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.55M, a 23.06% decline year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $13.36M, a 483.19% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $3.59M, a 85.63% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.71M, a 101.25% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS share-based payment arrangement, noncash expense for fiscal 2025 was $12.90M, a 77.12% increase from fiscal 2024.
- MOONLAKE IMMUNOTHERAPEUTICS share-based payment arrangement, noncash expense for fiscal 2024 was $7.28M, a 2.48% increase from fiscal 2023.
- MOONLAKE IMMUNOTHERAPEUTICS share-based payment arrangement, noncash expense for fiscal 2023 was $7.11M, a 26.40% decline from fiscal 2022.
- MOONLAKE IMMUNOTHERAPEUTICS share-based payment arrangement, noncash expense for fiscal 2022 was $9.65M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 10 month | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $15.90M 10-Q · filed 2026-08-10 | $19.49M derived: sum of 3 quarters · filed 2026-08-10 | $23.20M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2026-03-31 | $13.36M 10-Q · filed 2026-05-11 | $16.95M derived: sum of 2 quarters · filed 2026-05-11 | $20.65M derived: sum of 3 quarters · filed 2026-05-11 | $23.96M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-12-31 | $3.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $7.30M derived: sum of 2 quarters · filed 2026-02-25 | $10.61M derived: sum of 3 quarters · filed 2026-08-10 | $12.90M 10-K · filed 2026-02-25 | |||||
| 2025-09-30 | $3.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $7.02M derived: sum of 2 quarters · filed 2026-08-10 | $9.31M 10-Q · filed 2025-11-05 | $11.24M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-06-30 | $3.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $5.60M 10-Q · filed 2026-08-10 | $7.53M derived: sum of 3 quarters · filed 2026-08-10 | $9.38M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-03-31 | $2.29M 10-Q · filed 2026-05-11 | $4.22M derived: sum of 2 quarters · filed 2026-05-11 | $6.07M derived: sum of 3 quarters · filed 2026-05-11 | $7.89M derived: sum of 4 quarters · filed 2026-05-11 | |||||
| 2024-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.78M derived: sum of 2 quarters · filed 2026-02-25 | $5.61M derived: sum of 3 quarters · filed 2026-02-25 | $7.28M 10-K · filed 2026-02-25 | $7.28M 10-K · filed 2025-02-26 | ||||
| 2024-09-30 | $1.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.67M derived: sum of 2 quarters · filed 2025-11-05 | $5.35M 10-Q · filed 2025-11-05 | $5.35M 10-Q · filed 2024-11-07 | $6.95M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $3.50M 10-Q · filed 2025-08-05 | $3.51M 10-Q · filed 2024-08-07 | $5.11M derived: sum of 3 quarters · filed 2026-02-25 | $6.54M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $1.68M 10-Q · filed 2025-05-12 | $1.68M 10-Q · filed 2024-05-07 | $3.28M derived: sum of 2 quarters · filed 2026-02-25 | $4.71M derived: sum of 3 quarters · filed 2026-02-25 | $6.21M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.03M derived: sum of 2 quarters · filed 2026-02-25 | $4.53M derived: sum of 3 quarters · filed 2026-02-25 | $7.11M 10-K · filed 2026-02-25 | $7.11M 10-K · filed 2024-02-29 | ||||
| 2023-09-30 | $1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.92M derived: sum of 2 quarters · filed 2024-11-07 | $5.50M 10-Q · filed 2024-11-07 | $8.10M derived: sum of 4 quarters · filed 2025-02-26 | |||||
| 2023-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $4.07M 10-Q · filed 2024-08-07 | $6.67M derived: sum of 3 quarters · filed 2025-02-26 | $9.26M derived: sum of 4 quarters · filed 2025-02-26 | |||||
| 2023-03-31 | $2.58M 10-Q · filed 2024-05-07 | $5.17M derived: sum of 2 quarters · filed 2025-02-26 | $7.76M derived: sum of 3 quarters · filed 2025-02-26 | $10.24M derived: sum of 4 quarters · filed 2025-02-26 | |||||
| 2022-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $5.18M derived: sum of 2 quarters · filed 2025-02-26 | $7.67M derived: sum of 3 quarters · filed 2025-02-26 | $9.65M 10-K · filed 2025-02-26 | |||||
| 2022-09-30 | $2.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $5.07M derived: sum of 2 quarters · filed 2023-11-14 | $7.06M 10-Q · filed 2023-11-14 | ||||||
| 2022-06-30 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $4.47M 10-Q · filed 2023-08-10 | |||||||
| 2022-03-31 | $1.99M 10-Q · filed 2023-05-11 | ||||||||
| 2021-12-31 | $9.05M 10-K · filed 2023-03-20 | ||||||||
| 2021-09-30 | $1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $3.11M 10-Q · filed 2022-11-14 | |||||||
| 2021-06-30 | $1.25M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |